CLOBETASOL PROPIONATE
Clinical safety rating: safe
Animal studies have demonstrated safety
Corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines and suppression of immune response via modulation of gene expression.
| Metabolism | Primarily hepatic via CYP3A4; systemic absorption minimal with topical use but can be significant with extensive application or occlusion. |
| Excretion | Primarily fecal (biliary) with minimal renal excretion. Less than 5% of a topical dose is recovered in urine as metabolites; the majority is eliminated via feces after hepatic metabolism. |
| Half-life | Terminal elimination half-life is approximately 2-3 hours after topical application. However, due to prolonged cutaneous retention, clinical effects may persist beyond systemic elimination. |
| Protein binding | Approximately 96-99% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (transcortin). |
| Volume of Distribution | Not well characterized after topical use due to minimal systemic absorption. After intravenous administration in studies, Vd is approximately 1.0 L/kg, indicating distribution into total body water. |
| Bioavailability | Topical: Minimal systemic absorption, typically <5% through intact skin, but can increase to 20-30% in areas with compromised barrier (e.g., inflamed skin, occlusive dressings). Oral: Not applicable; clobetasol is not administered orally due to extensive first-pass metabolism. |
| Onset of Action | Topical: Visible improvement in 24-48 hours for dermatoses; intralesional: onset within minutes to hours for local anti-inflammatory effect. |
| Duration of Action | Topical: Duration of effect for dermatoses is 12-24 hours after a single application, requiring twice-daily dosing for sustained suppression. Intralesional: effects may last 1-2 weeks. |
Apply topically as a thin film to affected areas once to twice daily. Maximum 50 g/week. Treatment duration not to exceed 2 consecutive weeks.
| Dosage form | LOTION |
| Renal impairment | No dose adjustment required for topical use. Systemic absorption is minimal; however, use with caution in severe renal impairment due to potential for increased systemic exposure. |
| Liver impairment | No specific dose adjustment guidelines for topical use. Caution in severe hepatic impairment (Child-Pugh C) due to potential for decreased metabolism and increased systemic effects. |
| Pediatric use | Not recommended for children under 12 years of age due to increased risk of systemic toxicity. For children 12 and older, apply sparingly to affected area once to twice daily, limit to small areas, and use for shortest duration necessary (typically ≤2 weeks). |
| Geriatric use | Use with caution due to higher risk of skin atrophy and systemic absorption. Apply sparingly to affected areas, limit treatment duration, and avoid occlusive dressings. Consider intermittent dosing schedules. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Systemic absorption can cause reversible HPA axis suppression with potential for glucocorticosteroid insufficiency.
| Breastfeeding | Excretion into breast milk is unknown. M/P ratio not available. Caution is advised; apply sparingly and avoid breastfeeding immediately after application to minimize infant exposure. Do not apply to breast area. |
| Teratogenic Risk | Pregnancy category C. In animal studies, corticosteroids have been shown to be teratogenic. Topical application of clobetasol propionate in pregnant animals resulted in fetal abnormalities. In humans, sufficient data are lacking. Risk cannot be ruled out; use only if potential benefit justifies risk. First trimester: avoid due to theoretical risk of cleft palate; second and third trimesters: use with caution, avoid prolonged or extensive use. |
■ FDA Black Box Warning
No boxed warning.
| Common Effects | Skin atrophy |
| Serious Effects |
["Hypersensitivity to clobetasol propionate or any component of the formulation","Untreated bacterial, fungal, or viral skin infections","Topical application in the eyes or periorbital area"]
| Precautions | ["Cushing's syndrome","Hypothalamic-pituitary-adrenal axis suppression with prolonged use","Rebound effect upon discontinuation","Skin atrophy, striae, telangiectasias","Systemic toxicity if used on large surface areas","Not recommended for use on face, groin, or axillae due to increased risk of atrophy","Avoid in patients with known hypersensitivity to corticosteroids"] |
Loading safety data…
| Fetal Monitoring | Monitor for maternal adrenal suppression, skin atrophy, and infection. In fetus or neonate, monitor for signs of intrauterine growth restriction (IUGR) and adrenal insufficiency if used extensively. Consider growth scans if chronic use in pregnancy. |
| Fertility Effects | No adequate studies on fertility in humans. In animal studies, corticosteroids at high doses may impair fertility. Limited data; no specific recommendations for fertility effects. |